SMBG has been shown to be effective
overall in all patients with T2DM and is
associated with significantly greater glycemic lowering than the use of
conventional testing patterns.
Exenatide or liraglutide have a role in the treatment of T2DM as monotherapy or in addition to oral antidiabetic drugs.
indicates that perinatal morbidity (e.g., macrosomia, birth trauma,
neonatal metabolic complications) increases with increasing maternal